# OnCo record kras-wild-type-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/kras-wild-type-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "kras-wild-type-pdac" ;
  schema:name "KRAS wild-type pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "KRAS wild-type pancreatic cancer"@en, "KRAS-negative PDAC"@en, "Fusion-driven pancreatic cancer"@en, "BRAF-altered pancreatic cancer"@en ;
  schema:description "KRAS wild-type pancreatic cancer is the one in ten pancreatic cancers without the KRAS mutation that drives the rest. Instead many carry a different switched-on gene, often a fusion involving NRG1, NTRK, ALK, ROS1, FGFR2 or RET, or a BRAF change, and several of these have approved pills or antibodies, so these tumours must be sequenced with a test that detects fusions."@en ;
  schema:url <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/>, <https://onco.cc/cancers/ampullary/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/her3/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/nimotuzumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/folfirinox/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/notable-trial/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/anirban-maitra/>, <https://onco.cc/people/shen-lin/>, <https://onco.cc/people/eric-van-cutsem/> ;
  onco:pipeline <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/nimotuzumab/>, <https://onco.cc/trials/notable-trial/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/ideas/idea-prev-reflex-germline-testing/> ;
  onco:standardOfCare <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/targets/braf/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/drugs/nimotuzumab/>, <https://onco.cc/trials/notable-trial/>, <https://onco.cc/drugs/gemcitabine/> .